308 related articles for article (PubMed ID: 31678384)
1. Nanoformulations of small molecule protein tyrosine kinases inhibitors potentiate targeted cancer therapy.
Yin Y; Yuan X; Gao H; Yang Q
Int J Pharm; 2020 Jan; 573():118785. PubMed ID: 31678384
[TBL] [Abstract][Full Text] [Related]
2. Targeting non-receptor tyrosine kinases using small molecule inhibitors: an overview of recent advances.
Hojjat-Farsangi M
J Drug Target; 2016; 24(3):192-211. PubMed ID: 26211367
[TBL] [Abstract][Full Text] [Related]
3. Tyrosine kinase inhibitors and their unique therapeutic potentialities to combat cancer.
Zhao Y; Bilal M; Raza A; Khan MI; Mehmood S; Hayat U; Hassan STS; Iqbal HMN
Int J Biol Macromol; 2021 Jan; 168():22-37. PubMed ID: 33290765
[TBL] [Abstract][Full Text] [Related]
4. ABC transporters in multi-drug resistance and ADME-Tox of small molecule tyrosine kinase inhibitors.
Deng J; Shao J; Markowitz JS; An G
Pharm Res; 2014 Sep; 31(9):2237-55. PubMed ID: 24842659
[TBL] [Abstract][Full Text] [Related]
5. Recent Advances in the Discovery of Multitargeted Tyrosine Kinase Inhibitors as Anticancer Agents.
Guo T; Ma S
ChemMedChem; 2021 Feb; 16(4):600-620. PubMed ID: 33179854
[TBL] [Abstract][Full Text] [Related]
6. Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective.
Yang Y; Li S; Wang Y; Zhao Y; Li Q
Signal Transduct Target Ther; 2022 Sep; 7(1):329. PubMed ID: 36115852
[TBL] [Abstract][Full Text] [Related]
7. Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update of recent developments.
Steeghs N; Nortier JW; Gelderblom H
Ann Surg Oncol; 2007 Feb; 14(2):942-53. PubMed ID: 17103252
[TBL] [Abstract][Full Text] [Related]
8. Emerging Importance of Tyrosine Kinase Inhibitors against Cancer: Quo Vadis to Cure?
Mongre RK; Mishra CB; Shukla AK; Prakash A; Jung S; Ashraf-Uz-Zaman M; Lee MS
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769090
[TBL] [Abstract][Full Text] [Related]
9. Protein Tyrosine Signaling and its Potential Therapeutic Implications in Carcinogenesis.
Kim M; Baek M; Kim DJ
Curr Pharm Des; 2017 Nov; 23(29):4226-4246. PubMed ID: 28625132
[TBL] [Abstract][Full Text] [Related]
10. Acquired platelet antagonism: off-target antiplatelet effects of malignancy treatment with tyrosine kinase inhibitors.
Tullemans BME; Heemskerk JWM; Kuijpers MJE
J Thromb Haemost; 2018 Sep; 16(9):1686-1699. PubMed ID: 29975003
[TBL] [Abstract][Full Text] [Related]
11. Hypoxia modulates the activity of a series of clinically approved tyrosine kinase inhibitors.
Ahmadi M; Ahmadihosseini Z; Allison SJ; Begum S; Rockley K; Sadiq M; Chintamaneni S; Lokwani R; Hughes N; Phillips RM
Br J Pharmacol; 2014 Jan; 171(1):224-36. PubMed ID: 24117380
[TBL] [Abstract][Full Text] [Related]
12. Tyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters: substrates, chemosensitizers or inducers of acquired multidrug resistance?
Brózik A; Hegedüs C; Erdei Z; Hegedus T; Özvegy-Laczka C; Szakács G; Sarkadi B
Expert Opin Drug Metab Toxicol; 2011 May; 7(5):623-42. PubMed ID: 21410427
[TBL] [Abstract][Full Text] [Related]
13. Protein kinases as targets for cancer treatment.
Giamas G; Stebbing J; Vorgias CE; Knippschild U
Pharmacogenomics; 2007 Aug; 8(8):1005-16. PubMed ID: 17716234
[TBL] [Abstract][Full Text] [Related]
14. Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance.
Shukla S; Chen ZS; Ambudkar SV
Drug Resist Updat; 2012; 15(1-2):70-80. PubMed ID: 22325423
[TBL] [Abstract][Full Text] [Related]
15. Management of dose variability and side effects for individualized cancer pharmacotherapy with tyrosine kinase inhibitors.
Terada T; Noda S; Inui K
Pharmacol Ther; 2015 Aug; 152():125-34. PubMed ID: 25976912
[TBL] [Abstract][Full Text] [Related]
16. Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001-2020).
Huang L; Jiang S; Shi Y
J Hematol Oncol; 2020 Oct; 13(1):143. PubMed ID: 33109256
[TBL] [Abstract][Full Text] [Related]
17. Role of tyrosine kinase inhibitors in cancer therapy.
Arora A; Scholar EM
J Pharmacol Exp Ther; 2005 Dec; 315(3):971-9. PubMed ID: 16002463
[TBL] [Abstract][Full Text] [Related]
18. Polymorphisms to predict outcome to the tyrosine kinase inhibitors gefitinib, erlotinib, sorafenib and sunitinib.
Erdem L; Giovannetti E; Leon LG; Honeywell R; Peters GJ
Curr Top Med Chem; 2012; 12(15):1649-59. PubMed ID: 22978339
[TBL] [Abstract][Full Text] [Related]
19. Advances in studies of tyrosine kinase inhibitors and their acquired resistance.
Jiao Q; Bi L; Ren Y; Song S; Wang Q; Wang YS
Mol Cancer; 2018 Feb; 17(1):36. PubMed ID: 29455664
[TBL] [Abstract][Full Text] [Related]
20. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
Faivre S; Djelloul S; Raymond E
Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
